CND Life Sciences, Phoenix, Ariz, announced its national collaboration with NuFactor, Temecula, Calif, a specialty infusion company and subsidiary of FFF Enterprises, to educate neurologists on the availability and application of the Syn-One Test.

The collaboration focuses on engaging neuromuscular specialists and general neurologists in the United States who treat patients with signs and symptoms of synucleinopathies, including Parkinson’s disease, multiple system atrophy, and pure autonomic failure. For a significant percentage of patients, physicians lack objective pathological proof to help confirm a more definitive diagnosis for this group of neurodegenerative disorders.

“We are very pleased to partner with NuFactor to introduce our Syn-One Test to neurologists across the country and educate them on how the technology can be used to assist in the diagnosis of serious neurological disorders like Parkinson’s disease,” says Rick Morello, president and chief executive officer, CND Life Sciences. “NuFactor has been serving the needs of neuromuscular specialists and their patients for more than two decades and they are an ideal collaborator to help us make the Syn-One Test available for clinical care nationally.”

The Syn-One Test is a breakthrough in diagnosing a group of neurodegenerative diseases called synucleinopathies, according to CND Life Sciences. These serious disorders share a common pathological marker, an abnormal form of a protein known as alpha-synuclein that accumulates in nerve cells and causes progressive decline in neurological functions. The company says Syn-One is the only commercially available test that uses a simple skin biopsy to make it easy for physicians and patients to obtain visual, pathological proof of abnormal alpha-synuclein, increasing confidence in the diagnosis and subsequent treatment plan.

“We are extremely excited to partner with CND Life Sciences on this important initiative to help diagnose those living with synucleinopathies,” says Patrick Schmidt, chief executive officer, FFF Enterprises and NuFactor. “Through our specialty infusion pharmacy, we have developed strong relationships with neuromuscular specialists and others in the neurology community, thus making this the ideal partnership to help introduce Syn-One as a new and innovative technology to aid these patients.”

For more information, visit CND Life Sciences.

Featured image: Syn-One Test for diagnosing neurodegenerative diseases called synucleinopathies, including Parkinson’s. (Courtesy: CND Life Sciences)